Core Viewpoint - Pulmonx Corporation has successfully closed a five-year credit facility of up to $60 million with Perceptive Advisors, aimed at strengthening its capital structure and extending debt maturity to 2031 [1][2][3] Financing Details - The credit facility includes an initial $40 million term loan drawn at closing to refinance existing debt, with an option for an additional $20 million available until the end of 2027, contingent on achieving specific revenue milestones [2] - The facility is interest-only until maturity in 2031, with an interest rate set at one-month Term SOFR plus 7.0%, subject to a 3.75% floor, and allows for 2.0% of the interest to be paid-in-kind for three years [2] Strategic Implications - The new debt facility is expected to enhance the company's capital structure, allowing it to focus on executing its commercial strategy and advancing key clinical programs for its life-changing treatments for severe emphysema [3] - The Pulmonx Zephyr Valve is highlighted as a leading product with strong clinical evidence and broad reimbursement, addressing significant unmet needs for patients with severe emphysema [3] Company Overview - Pulmonx Corporation is a leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), with products like the Zephyr Endobronchial Valve and the Chartis Pulmonary Assessment System designed for patients with severe emphysema [5] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, recognized as a standard treatment option for improving quality of life in severe emphysema patients [5] Partner Overview - Perceptive Advisors, founded in 1999, manages approximately $8 billion and focuses on supporting advancements in the life sciences by directing financial resources to promising healthcare technologies [7]

Core Viewpoint - Boston Scientific plans to acquire Penumbra for approximately $14.5 billion, enhancing its cardiovascular and vascular intervention portfolio to meet the growing demand for minimally invasive treatments for blood clots and strokes [1][2]. Financial Details - The acquisition values Penumbra at $374 per share, a 19% premium over its closing price of $313.43 [2]. - The deal has an enterprise value of about $14.5 billion, excluding Penumbra's net cash and short-term investments of approximately $470 million [2]. - Boston Scientific intends to finance the $11 billion cash portion through a combination of cash on hand and new debt [3]. - The transaction is expected to be dilutive to adjusted earnings per share by $0.06 to $0.08 in the first year post-closing, neutral to slightly accretive in the second year, and increasingly accretive thereafter [3]. Strategic Rationale - The acquisition allows Boston Scientific to enter fast-growing segments within the vascular space, leveraging Penumbra's mechanical thrombectomy devices designed for blood clot removal [4]. - Penumbra's technologies are expected to complement Boston Scientific's existing offerings and expand access to advanced treatments globally [6]. Market Context - Cardiovascular diseases are the leading cause of death worldwide, driving demand for advanced treatment tools for conditions like pulmonary embolism and stroke [5]. - Penumbra anticipates fourth-quarter revenue growth of approximately 21.4% to 22.0%, with full-year 2025 revenue projected at around $1.4 billion, reflecting a growth of about 17.3% to 17.5% from the previous fiscal year [8][9]. Broader Acquisition Strategy - This announcement follows Boston Scientific's recent agreement to acquire Valencia Technologies Corporation, indicating a strategy to broaden its technology base across cardiovascular, neurovascular, and urology markets [10][11].